Gentium to Present at Rodman & Renshaw Techvest Seventh Annual Healthcare Conference
November 07 2005 - 10:12AM
Business Wire
Gentium S.p.A. (AMEX:GNT) (the "Company") announced today that
Laura Ferro, M.D., Chairman and Chief Executive Officer of Gentium,
will present a corporate update at the upcoming Rodman &
Renshaw Techvest Seventh Annual Healthcare Conference. The
presentation is scheduled for 11:15 a.m. (Eastern Time) on
Wednesday, November 9, 2005. The event will be held from November
7-9, 2005 at the New York Palace Hotel in New York. Individuals may
listen to a live web cast of the presentation by logging on to the
Investor Relations section of the Company's web site at
www.gentium.it a few minutes prior to the start time to download
any necessary software. The presentation will be archived for a
limited time. The Company's updated investor presentation can also
be viewed at the Investor Relations section of the Company's web
site. The conference will feature presentations from more than 290
public and privately held emerging growth healthcare companies
presenting data on an array of therapeutic topics including
oncology, cardiovascular disease, central nervous system disorders,
infectious diseases and medical device technology. Details
regarding the conference can be obtained at
www.rodmanandrenshaw.com. About the Company Gentium S.p.A. is a
biopharmaceutical company located in Villa Guardia (Como), Italy
that is focused on the research, discovery and development of drugs
derived from DNA extracted from natural sources, and drugs which
are synthetic derivatives, to treat and prevent a variety of
vascular diseases and conditions related to cancer and cancer
treatments. Defibrotide, the Company's lead product candidate in
the U.S., is an investigational drug that has been granted Orphan
Drug status by the U.S. FDA to treat veno-occlusive disease (VOD)
with multiple organ failure ("Severe VOD") and Fast Track
designation for the treatment of Severe VOD in recipients of stem
cell transplants. Cautionary Note Regarding Forward-Looking
Statements This press release contains "forward-looking
statements." In some cases, you can identify these statements by
forward-looking words such as "may," "might," "will," "should,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential" or "continue," the negative of these terms and other
comparable terminology. These statements are not historical facts
but instead represent the Company's belief regarding future
results, many of which, by their nature, are inherently uncertain
and outside the Company's control. It is possible that actual
results may differ, possibly materially, from those anticipated in
these forward-looking statements. For a discussion of some of the
risks and important factors that could affect future results, see
the discussion in our Prospectus filed with the Securities and
Exchange Commission under Rule 424(b)(4) under the caption "Risk
Factors."
Gentium Spa (AMEX:GNT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gentium Spa (AMEX:GNT)
Historical Stock Chart
From Sep 2023 to Sep 2024